

**APC/Fire™ 750 anti-human IL-2**

**Catalog # / Size:** 3101760 / 100 tests  
3101755 / 25 tests

**Clone:** MQ1-17H12

**Isotype:** Rat IgG2a, κ

**Immunogen:** *E. coli* - expressed recombinant human IL-2


**Reactivity:** Human, Non-human primate, Other

**Preparation:** The antibody was purified by affinity chromatography and conjugated with APC/Fire™ 750 under optimal conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Workshop Number:** VI MA36

**Concentration:** Lot-specific




PMA + ionomycin stimulated (6 hours) human peripheral blood mononuclear cells were stained with CD3 PerCP/Cyanine5.5 and then fixed, permeablized and stained with IL-2 (clone MQ1-17H12) APC/Fire™ 750 (left) or rat IgG2a, κ APC/Fire™ 750 isotype control (right).

**Applications:**

**Applications:** Intracellular Staining for Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood.



\* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

**Application Notes:** **ELISA or ELISPOT Capture<sup>2,3</sup>:** The purified MQ1-17H12 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the Biotin anti-human IL-2 antibody (Cat. No. 517605) as the detecting antibody. The Ultra-LEAF™ purified antibody is suggested for ELISPOT capture.

**Application  
References:**

1. Andersson J, et al. 1994. *Immunology* 83:16. (IHC)
2. Abrams J, et al. 1992. *Immunol. Rev.* 127:5. (IP)
3. Abrams JS. 1995. *Curr. Prot. Immunol.* Unit 6.20.
4. Fernandez V, et al. 1994. *Eur. J. Immunol.* 24:1808. (IHC)
5. Skansen-Saphir U, et al. 1994. *Eur. J. Immunol.* 24:916. (IHC)
6. Andersson U, et al. *Detection and Quantification of Gene Expression.* New York:Springer-Verlag. (IHC)
7. Prussin C, et al. 1995. *J. Immunol. Methods.* 188:117.
8. Raqib R, et al. 2002. *Infect. Immun.* 70:3199. (IHC)
9. Dzhagalov I, et al. 2007. *J. Immunol.* 178:2113. [PubMed](#)
10. Colleton BA, et al. 2009. *J Virol.* 83:6288. [PubMed](#)
11. Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
12. Rout N, et al. 2010. *PLoS One* 5:e9787. (FC)
13. Yeap SK, et al. 2013. *BMC Complement Altern. Med.* 13:145. (Neut)
14. Wu Z, et al. 2015. *J Virol.* 89:6435. [PubMed](#)
15. Maksareekul S, et al. 2009. *Vaccine.* 28:3754 (FC) [PubMed](#)

---

**Description:** IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells, promoting proliferation and maturation. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendrocytes.

**Antigen  
References:**

1. Fitzgerald K, et al. Eds. 2001. *The Cytokine FactsBook.* Academic Press, San Diego.
2. Taniguchi T, et al. 1993. *Cell* 73:5.
3. Nistico G. 1993. *Prog. Neurobiol.* 40:463.
4. Waldmann T, et al. 1993. *Ann. NY Acad. Sci.* 685:603.